drugset / Trial / NCT07300475
Personalized Cancer Vaccine (PCV) Strategy in Triple Negative Breast Cancer Patients
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a phase 1 clinical trial to evaluate the safety, feasibility and immunogenicity of a personalized cancer vaccine (PCV) strategy with or without CD8-selective IL-2 mutein fusion protein in patients with triple negative breast cancer undergoing neoadjuvant chemoimmunotherapy.
Timeline
- Start
- 2026-10-01
- Primary completion
- 2030-07-31
- Completion
- 2035-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Personalized cancer vaccine (PCV) | Vaccine | 1 mg | Intramuscular |
| Subject | etakafusp alfa | Protein / enzyme biologic | — | Intravenous |
| Background | Carboplatin | Small molecule | — | — |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Doxorubicin | Other / unclassified | — | — |
| Background | Hiltonol | Other / unclassified | — | — |
| Background | Paclitaxel | Small molecule | — | — |
| Background | Pembrolizumab | Monoclonal antibody | — | — |